

**SYNTHESIS, CHARACTERISATION AND
CYTOTOXICITY STUDY OF SOME NEW 1,2,4-
TRIAZOLE DERIVATIVES**

MUKHLIF MOHSIN SLAIHIM

**UNIVERSITI SAINS MALAYSIA
2017**

**SYNTHESIS, CHARACTERISATION AND
CYTOTOXICITY STUDY OF SOME NEW 1,2,4-
TRIAZOLE DERIVATIVES**

By

MUKHLIF MOHSIN SLAIHIM

**Thesis submitted in fulfillment of the requirements
for the degree of
Doctor of Philosophy**

March 2017

Saya isytiharkan bahawa kandungan yang dibentangkan di dalam tesis ini adalah hasil kerja saya sendiri dan telah dijalankan di Universiti Sains Malaysia kecuali dimaklumkan sebaliknya. Tesis ini juga tidak pernah diserahkan untuk ijazah yang lain sebelum ini.

I declare that the content which is presented in this thesis is my own work which was done at Universiti Sains Malaysia unless informed otherwise. The thesis has not been previously submitted for any other degree.

Disaksikan oleh:
Witnessed by:

.....
Tandatangan Calon:
Signature of student:

Nama calon:
Name of student:

MUKHLIF MOHSIN SLAIHIM

IC/Passport No: **A10673527**

.....
Tandatangan Penyelia:
Signature of Supervisor:

Nama Penyelia:
Name of supervisor:

**ASSOC. PROF. DR MELATI BINTI
KHAIRUDDEAN**

IC/Passport No: **650822075090**

ACKNOWLEDGEMENT

First of all, I bent my backbone before “Almighty Allah” who has grant me the chance and possibility to make this little material contribution to the already existing sea of knowledge and all respects are for the Holy Prophet, Hazrat Muhammad  who has guide us to recognize our Creator. It is a matter of great pleasure to express my obligations and sincere thanks to my research supervisor, Assoc. Prof. Dr. Melati Khairuddean for her continuous encouragement and keen interest and guidance throughout my research work. May Almighty Allah shower His blessings and prosperity on her who has assisted me in many ways during the completion of my research work.

I am thankful to the Government of Iraq, Institute of Ministry of higher education and scientific research in Iraq and Samarra University for providing me the scholarship as the financial support scholarship. I am also thankful to the Malaysian government, Institute of Postgraduate Studies and the School of Chemical Sciences, USM for providing me the support and all the facilities necessary for the completion of my research project. Special thanks goes to the Dean of the School of Chemical Sciences for the support given to me.

I am grateful to Dr. Mohamed Khadeer Ahmed and those from Eman’s Lab at Eureka for their help and provision of laboratory facilities to carry out the anticancer assays. I would also like to acknowledge the technical staff of School of Chemical Sciences, especially Mr. Muhd Nizam Muhamad, Mr. Zahari Othman, Mr. Azizo Daud, Mr. Razly Effendy, Mrs. Wan Zulilawati, Mrs. Nor Asma Ismail, Mr. Clement D’Silva, Mr. Megat Hasnul, Mr. Chow Cheng Por and Mr. Mohd Nazeef for their

help and technical support. I would also like to thank my friends and colleagues; Mohamed Ali Alwahsh, Nargis Jamila, Aboubaker Abdulnabi Elhadi, Tan Wen Nee, Francis Ezebor, Alireza Basiri, Yalda Kia, Siti Nurfatim Ahmad Kamal, Foong Shin Yee, Samina Khan, Basma, Alice Wong, Miyeko Lotus, Zuhair Jamain, Afiqah Hassim, Chong Mui Phin, Cheah June Sun and Soh Lee Leng for their help, cooperation and encouragements.

Finally, Special thanks to my beloved mother, my father-in-law and my mother-in-law who have given me all the support and never ending prayer. Also, special gratitude to my beloved wife and my children who gave their never ending patience, support and prayer which has stimulated me to finish my work. Without their encouragement and support, I would not be able to complete my work. My thanks also goes to my dear cousins and friends, who remember me in their prayers and hearts.

Thank you all,

Mukhlif Mohsin

March 2017

TABLE OF CONTENTS

Acknowledgment	ii
Table of Contents	iv
List of Tables	x
List of Figures	xii
List of Schemes	xvi
List of Abbreviations	xvii
Abstrak	xix
Abstract	xxi
CHAPTER 1 - INTRODUCTION	1
1.1 Background of the research work	1
1.2 Problem statement	5
1.3 Objectives	5
1.4 Scope of the Study	6
CHAPTER 2 - LITERATURE REVIEW	7
2.1 Compounds with 1,2,4-triazole core system	7
2.2 Schiff base 1,2,4-triazole derivatives	11
2.3 1,2,4-Triazolo[4,3-b][1,2,4]thiadiazole derivatives	17
2.4 1,2,4-Triazolo[4,3-b][1,2,4]triazole derivatives	19
2.5 1,2,4-Triazolo-3-thiolate derivatives	19
2.6 1,3,4-Oxadiazole-2-thiolate derivatives	20

CHAPTER 3 - EXPERIMENTAL AND METHODS	21
3.1	Chemicals 21
3.1.1	Chemicals and solvents used in the synthesis work 21
3.1.2	Reagents and chemicals used in the cytotoxicity assay 22
3.1.3	Tissue Culture materials 22
3.1.4	Cell Lines 23
3.2	General Experimental Methods 23
3.2.1	Drying of solvents 23
3.2.2	Melting Point 23
3.2.3	Thin Layer Chromatography (TLC) 23
3.2.4	Moisture-sensitive reactions 24
3.2.5	Recrystallization 24
3.3	Instruments 24
3.3.1	Infrared Spectroscopy (IR) 24
3.3.2	Nuclear Magnetic Resonance Spectroscopy (NMR) 24
3.3.3	Elemental analysis 25
3.3.4	Instruments for cytotoxic assay 25
3.4	Synthesis Methods 26
3.4.1	Synthesis of alkyl 4-substituted-benzoate, 1(Ba-Ea) and 1Db 27
3.4.2	Synthesis of acid hydrazide, 2(B-E) 29
3.4.3	Synthesis of potassium dithiocarbazinate salts, 3(A-D) 31
3.4.4	Synthesis of 5-aryl -1,3,4-oxadiazole-2-thiol, 4(A-D) 34
3.4.5	Synthesis of 4-amino-5-(4-sub-phenyl)-4 <i>H</i> -1,2,4-triazole-3-thiol, 5SA and 5(B-D) 36

3.4.6	Synthesis of 3-(pyridin-4-yl)-7 <i>H</i> -[1,2,4]triazolo[4,3- <i>b</i>] [1,2,4]triazol-6-amine, 6A	40
3.4.7	Synthesis of piperidinium (<i>Z</i>)- <i>N'</i> -4-amino-5-(4-sub-aryl)- 4 <i>H</i> -1,2,4-triazol-3-yl-carbamimidothioate, 7(A-B)	41
3.4.8	Synthesis of (<i>E</i>)-1-(4-methoxybenzylideneamino)-2-(4-sub- aryl)-1 <i>H</i> -[1,2,4]triazolo[1,5- <i>b</i>][1,2,4]triazole-6-thiol, 8(A-B)	43
3.4.9	Synthesis of 4-(5-thioxo-4-ureido-4,5-dihydro-1 <i>H</i> -1,2,4- triazol-3-yl) pyridinium chloride, 8SA	45
3.4.10	Synthesis of Schiff base compounds, from 4-(5-thioxo- 4-ureido-4, 5-dihydro-1 <i>H</i> -1,2,4-triazol-3-yl) pyridinium chloride, 8SA(a-d)	46
3.4.11	Synthesis of piperidinium 4-amino-5-(4-sub-aryl)-4 <i>H</i> -1,2,4- triazole-3-thiolate, 9(A-B)	49
3.4.12	Synthesis of Schiff base compounds from piperidinium 4-amino-5-(pyridin-4-yl)-4 <i>H</i> -1,2,4-triazole-3-thiolate, 9A	51
3.4.13	General procedure for preparation of Schiff base compounds, 9B₁-i-viii <i>via</i> conversion of 4-amino-5-(4-hydroxyphenyl)- 4 <i>H</i> -1,2,4-triazole-3-thiole, 5B	58
3.4.14	General procedure for preparation of Schiff base compounds, 9A₂-i-iv and 9B₂-i-iv <i>via</i> conversion of the piperidinium 4-amino-5-(4sub-phenyl)-4 <i>H</i> -1,2,4-triazole-3-thiolate, 9(A-B)	65
3.4.15	General procedure for preparation of 2,6-disubstituted-[1,2,4] triazolo[5,1- <i>b</i>][1,3,4]oxadiazole, 10B-1 , 10A-2 and 10C-3	72
3.4.15(a)	Synthesis of piperidinium 2-(4-hydroxyphenyl)-	

	[1,2,4]triazolo[5,1-b][1,3,4] oxadiazole-6-thiolate, 10B-1	72
3.4.15(b)	Synthesis of piperidinium 2-(pyridin-4-yl)-[1,2,4]triazolo [5,1-b][1,3,4]-oxadiazol-6-yl-carbamimido- thioate, 10A-2	73
3.4.15(c)	Synthesis of piperidinium 2-(4-bromophenyl)-[1,2,4]triazolo[5,1-b][1,3,4]-oxadiazole-6-yl-(cyano)carbamimidothioate, 10C-3	74
3.4.15(d)	Synthesis of piperidinium 1-amino-2-(4-sub-aryl)-1 <i>H</i> -[1,2,4]triazolo[1,5-b][1,2,4] triazol-6-yl(cyano)carbamimidothioate, 11(A-B)-3	75
3.5	Cytotoxicity Assay	77
3.5.1	Sample preparation for the cell proliferation assay	77
3.5.2	Cell Culturing	77
3.5.3	Cell Seeding into 96-well Plate	78
3.5.4	MTT cell proliferation assay (cell viability assay)	79
3.5.5	Determination of morphological changes	81
3.5.6	Statistical analysis	81
	CHAPTER 4 - RESULTS AND DISCUSSION	82
4.1	Structure determination of the ester compounds, 1(Ba-Ea) and 1Db	82
4.2	Structure determination of the acid hydrazide compounds, 2(B-E)	85
4.3	Structure determination of the potassium dithiocarbazinate salts, 3(A-D)	88
4.4	Structure determination of 5-aryl -1,3,4-oxadiazole-2-thiol derivatives, 4(A-D)	91

4.5	Structure determination of the 4-amino-5-(4-sub-phenyl)-4 <i>H</i> -1,2,4-triazole-3-thiol derivatives, 5SA and 5(B-D)	94
4.6	Structure determination of 3-(pyridin-4-yl)-7 <i>H</i> -[1,2,4]triazolo[4,3- <i>b</i>][1,2,4] triazol-6-amine, 6A	97
4.7	Structure determination of the piperidinium (<i>Z</i>)- <i>N'</i> -4-amino-5-(4-sub-phenyl)-4 <i>H</i> -1,2,4-triazol-3-yl-carbamimidothioate, 7(A-B)	100
4.8	Structure determination of the (<i>E</i>)-1-(4-methoxybenzylideneamino)-2-(4-Sub-Aryl)-1 <i>H</i> -[1,2,4] triazolo[1,5- <i>b</i>] [1,2,4]triazole-6-thiol, 8(A-B)	104
4.9	Structure determination of the 4-(5-thioxo-4-ureido-4,5-dihydro-1 <i>H</i> -1,2,4-triazol-3-yl) pyridinium chloride, 8SA	107
4.10	Structure determination of the piperidinium 4-amino-5-(4-sub-phenyl)-4 <i>H</i> -1,2,4-triazole-3-thiolate 9(A-B)	111
4.11	Structure determination of the conversion of piperidinium 4-amino-5-(4-Sub-Aryl)-4 <i>H</i> -1,2,4-triazole-3-thiolate 9(A-B) to Schiff base	117
4.12	Structure determination of 2,6-disubstituted-[1,2,4]triazolo[1,5- <i>b</i>][1,3,4]oxadiazole (10B-1 , 10A-2 and 10C-3) and piperidinium 2,6-disubstituted-1 <i>H</i> -[1,2,4]triazolo[1,5- <i>b</i>][1,2,4]triazole (11A-3)	131
4.13	Discussion on the reaction mechanism	138
	4.13.1 Reaction mechanism for the ester compounds, 1(Ba-Ea) and 1Db	138
	4.13.2 Reaction mechanism for the acid hydrazide compounds, 2(B-E)	138
	4.13.3 Reaction mechanism for potassium dithiocarbazinate salts, 3(A-D)	139

4.13.4	Reaction mechanism for 5-aryl-1,3,4-oxadiazole-2-thiol derivatives, 4(A-D)	140
4.13.5	Reaction mechanism of 4-amino-5-(4-sub-aryl)-4 <i>H</i> -1,2,4-triazole-3-thiol derivatives, 5SA and 5(B-D)	141
4.13.6	Reaction mechanism of 3-(pyridin-4-yl)-7 <i>H</i> -[1,2,4]triazolo[4,3- <i>b</i>][1,2,4]triazol-6-amine, 6A	142
4.13.7	Reaction mechanism of piperidinium (<i>Z</i>)- <i>N'</i> -4-amino-5-(4-sub-aryl)-4 <i>H</i> -1,2,4-triazol-3-ylcarbami-midothioate, 7(A-B)	143
4.13.8	Reaction mechanism of 4-(5-thioxo-4-ureido-4,5-dihydro-1 <i>H</i> -1,2,4-triazol-3-yl) pyridinium chloride, 8SA	144
4.13.9	Reaction mechanism of (<i>E</i>)-1-(4-methoxybenzylideneamino)-2-(4-sub-aryl)-1 <i>H</i> -[1,2,4] triazolo[1,5- <i>b</i>][1,2,4]triazole-6-thiol, 8(A-B)	145
4.13.10	Reaction mechanism of piperidinium 2,6-disubstituted-[1,2,4] triazolo [5,1 <i>b</i>][1,3,4]oxadiazole (10B-1 , 10A-2 & 10C-3) and 2,6-disubstituted-1 <i>H</i> [1,2,4]triazolo[1,5 <i>b</i>][1,2,4]triazole, (11A-3)	147
CHAPTER 5 - CYTOTOXICITY STUDY		149
5.1	The selected compounds for cytotoxicity study	149
5.2	Cytotoxic effect of the synthesised compounds on MCF-7 cells	150
5.3	Cytotoxic effect of the synthesised compounds on HCT 116 cells	158
5.4	The structure-activity relationship	163
CHAPTER 6 - CONCLUSION		165
REFERENCES		167
APPENDIX		176

LIST OF TABLES

		Page
Table 4.1	IR, ¹ H and ¹³ C-NMR data of methyl-4-substituted-benzoate derivatives	83
Table 4.2	IR, ¹ H and ¹³ C-NMR data of the substituted acid hydrazide compounds	86
Table 4.3	IR, ¹ H and ¹³ C-NMR data of potassium dithiocarbazinate salts	89
Table 4.4	IR, ¹ H and ¹³ C-NMR data of 5-aryl -1,3,4-oxadiazole-2-thiol Derivatives	92
Table 4.5	IR, ¹ H and ¹³ C-NMR data of 4-amino-5-(4-sub-phenyl)-4 <i>H</i> -1,2,4-triazole-3-thiol derivatives	95
Table 4.6	IR, ¹ H and ¹³ C-NMR data of 6A	100
Table 4.7	IR, ¹ H and ¹³ C-NMR of piperidinium (<i>Z</i>)- <i>N'</i> -4-amino-5-(4-sub-phenyl)-4 <i>H</i> -1,2,4-triazol-3-yl-carbamimidothioate, 7(A-B)	104
Table 4.8	IR, ¹³ C and ¹ H-NMR spectral data of 8(A-B)	107
Table 4.9	FT-IR, ¹ H and ¹³ C-NMR data of 8SA	110
Table 4.10	FT-IR, ¹ H NMR and ¹³ C NMR of 9(A-B)	113
Table 4.11	IR characteristic bands of 9A_{1-i-viii} series with 4-pyridyl-(sub-aryl group) and 9B_{1-i-viii} series with 4-phenolyl-(sub-aryl group) and different sub-phenyl group	119
Table 4.12	IR characteristic bands of 9A_{2-i-iv} and 9B_{2-i-iv} series	120
Table 4.13	¹ H-NMR characteristic peaks of 9A_{1-i-viii} series with 4-pyridyl-(sub-aryl group) and different sub-phenyl group	125
Table 4.14	¹ H-NMR characteristic peaks of 9B_{1-i-viii} series with	

	4-phenolyl-(sub-aryl group) and different sub-phenyl group	126
Table 4.15	¹ H-NMR characteristic peaks of 9(A2i-iv) and 9(B2i-iv) series	127
Table 4.16	¹³ C-NMR characteristic peaks of 9(A1i-viii) with 4-pyridyl (sub-aryl group) and different sub-phenyl group	128
Table 4.17	¹³ C-NMR characteristic peaks of 9(B1i-viii) with 4-phenolyl (sub-aryl group) and different sub-phenyl group	129
Table 4.18	¹³ C-NMR characteristic peaks of 9(A2i-iv) and 9(B2i-iv) series.	130
Table 4.19	FT-IR, ¹ H NMR and ¹³ C NMR of 10B-1 , 10A-2 , 10C-3 and 11A-3	131
Table 5.1	IC ₅₀ values of some selected compounds against the MCF-7 cells	151
Table 5.2	Morphological features vs predicted mechanism	156
Table 5.3	IC ₅₀ values of some selected compounds against the HCT 116 cell	159

LIST OF FIGURES

		Page
Figure 2.1	Cyclisation of 1,2,4-triazole and 1,3,4-oxadiazole derivatives	8
Figure 4.1	IR spectrum of methyl 4-nitrobenzoate, 1Da	84
Figure 4.2	¹ H-NMR spectrum of 1Da (500 MHz, DMSO-d ₆)	84
Figure 4.3	¹³ C-NMR spectrum of 1Da (125 MHz, DMSO-d ₆)	85
Figure 4.4	IR spectrum of 4-nitrobenzoic acid hydrazide, 2D	87
Figure 4.5	¹ H-NMR spectrum of 2D (500 MHz, DMSO-d ₆)	87
Figure 4.6	¹³ C-NMR spectrum of 2D (125 MHz, DMSO-d ₆)	88
Figure 4.7	IR spectrum of potassium 2-isonicotinoyl hydrazine-carbodithioate, 3A	90
Figure 4.8	¹ H-NMR spectrum of 3A (500 MHz, D ₂ O)	90
Figure 4.9	¹³ C-NMR spectrum of 3A (125 MHz, D ₂ O)	91
Figure 4.10	IR spectrum of 5-(4-hydroxyphenyl)-1,3,4-oxadiazole-2-thiol, 4B	93
Figure 4.11	¹ H-NMR spectrum of 4B (500 MHz, DMSO-d ₆)	93
Figure 4.12	¹³ C-NMR spectrum of 4B (125 MHz, DMSO-d ₆)	94
Figure 4.13	IR spectrum of 4-amino-5-(pyridin-4-yl)-4H-[1,2,4]triazole-3-thiol hydrochloride, 5SA	96
Figure 4.14	¹ H-NMR spectrum of 5SA (500 MHz, DMSO-d ₆)	97
Figure 4.15	¹³ C-NMR spectrum of 5SA (125 MHz, DMSO-d ₆)	97
Figure 4.16	IR spectrum of 3-(pyridin-4-yl)-7H-[1,2,4]triazolo[4,3-b][1,2,4]triazol-6-amine, 6A	98
Figure 4.17	¹ H-NMR spectrum of 6A (500 MHz, DMSO-d ₆)	99
Figure 4.18	¹³ C-NMR spectrum of 6A (125 MHz, DMSO-d ₆)	99

Figure 4.19	IR spectrum of 7A	101
Figure 4.20	¹ H-NMR spectrum of 7A (500 MHz, DMSO-d ₆)	101
Figure 4.21	¹³ C-NMR spectrum of 7A (125 MHz, DMSO-d ₆)	102
Figure 4.22	DEPT135 NMR spectrum of 7A (500 MHz, DMSO-d ₆)	102
Figure 4.23	¹ H- ¹ H COSY NMR spectrum of 7A (500 MHz, DMSO-d ₆)	103
Figure 4.24	¹ H- ¹³ C HMQC-NMR spectrum of 7A (125 MHz, DMSO-d ₆)	103
Figure 4.25	IR spectrum of 8B	105
Figure 4.26	¹ H-NMR spectrum of 8B (500 MHz, DMSO-d ₆)	106
Figure 4.27	¹³ C-NMR spectrum of 8B (125 MHz, DMSO-d ₆)	106
Figure 4.28	IR spectrum of 8SA	108
Figure 4.29	¹ H-NMR spectrum of 8SA (500 MHz, DMSO-d ₆)	109
Figure 4.30	¹³ C-NMR spectrum of 8SA (125 MHz, DMSO-d ₆)	109
Figure 4.31	IR spectrum of 9A	112
Figure 4.32	¹ H-NMR spectrum of 9A (500 MHz, DMSO-d ₆)	114
Figure 4.33	¹³ C-NMR spectrum of 9A (125 MHz, DMSO-d ₆)	114
Figure 4.34	DEPT135 NMR spectrum of 9A (500 MHz, DMSO-d ₆)	115
Figure 4.35	¹ H- ¹ H COSY NMR spectrum of 9A (500 MHz, DMSO-d ₆)	116
Figure 4.36	¹ H- ¹³ C HMQC NMR spectrum of 9A (500 MHz, DMSO-d ₆)	116
Figure 4.37	¹ H- ¹³ C HMBC NMR spectrum of 9A (500 MHz, DMSO-d ₆)	117
Figure 4.38	IR spectrum of 9A1-i	118
Figure 4.39	¹ H-NMR spectrum of 9A1-i (500 MHz, DMSO-d ₆)	121
Figure 4.40	¹³ C-NMR spectrum of 9A1-i (125 MHz, DMSO-d ₆)	121
Figure 4.41	DEPT135 NMR spectrum of 9A1-i (500 MHz, DMSO-d ₆)	122
Figure 4.42	¹ H- ¹ H COSY NMR spectrum of 9A1-i (500 MHz, DMSO-d ₆)	123
Figure 4.43	¹ H- ¹³ C HMQC NMR spectrum of 9A1-i (500 MHz, DMSO-d ₆)	123

Figure 4.44	^1H - ^{13}C HMBC NMR spectrum of 9A₁-i (500 MHz, DMSO- d_6)	124
Figure 4.45	IR spectrum of 11A-3	133
Figure 4.46	^1H NMR spectrum of 11A-3 (500 MHz, DMSO- d_6)	134
Figure 4.47	^{13}C NMR spectrum of 11A-3 (125 MHz, DMSO- d_6)	134
Figure 4.48	DEPTQ NMR spectrum of 11A-3 (500 MHz, DMSO- d_6)	135
Figure 4.49	DEPT135 NMR spectrum of 11A-3 (500 MHz, DMSO- d_6)	136
Figure 4.50	^1H - ^1H COSY NMR spectrum of 11A-3 (500 MHz, DMSO- d_6)	136
Figure 4.51	^1H - ^{13}C HMQC NMR spectrum of 11A-3 (500 MHz, DMSO- d_6)	137
Figure 4.52	^1H - ^{13}C HMBC NMR spectrum of 11A-3 (500 MHz, DMSO- d_6)	137
Figure 4.53	The reaction mechanism of acid hydrazide	139
Figure 4.54	The reaction mechanism of potassium dithiocarbazinate salts	140
Figure 4.55	The reaction mechanism of 5-aryl-1,3,4-oxadiazole-2-thiol derivatives	141
Figure 4.56	The reaction mechanism of 3-(pyridin-4-yl)-7 <i>H</i> -[1,2,4]-triazolo-[4, 3- <i>b</i>][1,2,4]-triazol-6-amine, 6A	143
Figure 4.57	The reaction mechanism of piperidinium (<i>Z</i>)- <i>N'</i> -4-amino-5-(4-sub-aryl)-4 <i>H</i> -1,2,4-triazol-3-ylcarbami-midothioate, 7(A-B)	144
Figure 4.58	The reaction mechanism of 4-(5-thioxo-4-ureido-4,5-dihydro-1 <i>H</i> -1,2,4-triazol-3-yl) pyridinium chloride, 8SA	145
Figure 4.59	The reaction mechanism of (<i>E</i>)-1-(4-methoxybenzylidene-amino)-2-(4-Sub-Aryl)-1 <i>H</i> -[1,2,4]triazolo[1,5- <i>b</i>][1,2,4]triazole-6-thiol, 8(A-B)	146
Figure 4.60	The reaction mechanism of 10B-1 , 10A-2 , 10C-3 and 11A-3	148

Figure 5.1	Dose-dependent response for the samples 6A, 7A, 7B, 8A and 9A2-ii on MCF-7 cells.	153
Figure 5.2	Dose-dependent response for the samples 4B, 5SA, 5B, 8B, 9B1-ii,iii on MCF-7 cells.	154
Figure 5.3	Dose-dependent response for the samples 8SA, 9B1-iv,v,viii and 9A2-i on MCF-7 cells.	154
Figure 5.4	Images of human breast cancer (MCF-7) cell under an inverted phase-contrast microscope with a digital camera at 48 hours after treatment with compounds 4B, 5SA, 6A and 7A . The reference standard is Tamoxifen and treated cell group with 0.1% DMSO as negative control, NC (Magnification \times 200).	157
Figure 5.5	Images of human breast cancer (MCF-7) cell under an inverted phase-contrast microscope with a digital camera at 48 hours after treatment with the compounds 7B, 8A, 8B, 9B1-i,iii and 9A2-ii (Magnification \times 200).	158
Figure 5.6	Dose-dependent response for the samples 9B1-iii,iv,v,vi,vii and 9A2-i,ii on HCT 116 cells.	160
Figure 5.7	Dose-dependent response for the samples 9A2-iii, 9B2-i,ii,iii, 10C-3 and 11A-3 on HCT 116 cells.	161
Figure 5.8	Images of human colorectal tumor (HCT 116) cell under an inverted phase-contrast microscope with a digital camera at 48 hours (Magnification \times 200).	162

LIST OF SCHEMES

	Page
Scheme 3.1 Synthesis pathways of 4-amino-5-(4-substituted-phenyl)- 4 <i>H</i> -1,2,4-triazole-3-thiol, 5SA and (5B-5E)	26
Scheme 3.2 Synthesis pathways for Schiff base compounds	51
Scheme 3.3 Synthesis pathway of compounds 10B-1 , 10A-2 and 10C-3	72
Scheme 3.4 Synthesis pathway of compounds 11(A-B)-3	75

LIST OF SYMBOLS & ABBREVIATIONS

^1H -NMR	Proton Nuclear Magnetic Resonance
^{13}C -NMR	Carbon Nuclear Magnetic Resonance
IR	Infra-Red
Mol. Wt.	Molecular weight
HCl	Hydrochloric Acid
MeOD- d_4	Deuterated Methanol
CDCl ₃	Deuterated Chloroform
DMSO- d_6	Deuterated Dimethyl sulfoxide
C ₅ D ₅ N	Deuterated Pyridine
D ₂ O	Deuterium oxide
FT-IR	Fourier Transformer Infrared
1D-NMR	One Dimensional Nuclear Magnetic Resonance
2D-NMR	Two Dimensional Nuclear Magnetic Resonance
COSY	Correlation Spectroscopy
DEPT	Distortionless enhancement by Polarization Transfer
HMBC	Heteronuclear Multiple Bond Correlation
HMQC	Heteronuclear Multiple Quantum Correlation
HSQC	Heteronuclear Single Quantum Correlation
MIC	Minimum Inhibitory Concentration
TLC	Thin layer chromatography
R_f	Retention factor
MHz	Mega Hertz
br. <i>s</i>	Broad Singlet
br. <i>d</i>	Broad Doublet

<i>t</i>	Triplet
<i>q</i>	Quartet
<i>m</i>	Multiplet
ppm	Parts per million
cm ⁻¹	Per centimeter
δ	Chemical shift
μg	Micrograms
mg	Milligram
g	Gram
mL	Milliliter
s	Singlet
d	Doublet
nm	Nanometer
°C	Degree Celsius
h	Hour
min	Minutes
conc.	Concentration
cm	Centimeter
$\mu\text{g mL}^{-1}$	Microgram per milliliter
μL	Microliter
μM	Micromole
IC ₅₀	The half maximal inhibitory concentration
EC ₅₀	The half maximal effective concentration
λ_{max}	Lambda (Maximum Wavelength)

SINTESIS, PENCIRIAN DAN KAJIAN SITOTOKSIK BAGI BEBERAPA TERBITAN BARU 1,2,4-TRIAZOL

ABSTRAK

Dalam kajian ini, 36 sebatian baru 1,2,4-triazol dengan sistem gelang mono dan terlakur telah disintesis dan dicirikan. Sistem mono bagi terbitan 1,2,4-triazol mempunyai kumpulan yang berbeza terikat pada gelang triazol. Sistem mono yang pertama menunjukkan empat sebatian garam piridinium dan bes Schiff terikat pada gelang triazol manakala sistem mono yang kedua menunjukkan 24 sebatian garam piperidinium dan bes Schiff terikat pada gelang triazol. Sistem terlakur bagi terbitan 1,2,4-triazol termasuk tiga sebatian dengan gelang terlakur triazol-oksadiazol dan lima sebatian dengan gelang terlakur triazol-triazol. Kesemua sebatian ini telah dicirikan menggunakan spektroskopi Inframerah Transformasi Fourier (FT-IR) dan Resonan Nuklear Magnetik (NMR) dan analisa unsur karbon, hidrogen dan nitrogen (CHN). Beberapa sebatian telah dipilih untuk ujian sitotoksik dalam mencari agen anti kanser yang berpotensi, terutamanya untuk sel kanser payudara manusia (MCF-7) dan sel kanser kolon manusia (HCT 116). Sebanyak 35 sebatian yang terdiri daripada sembilan bahan perantara dan 26 hasil akhir telah dipilih untuk asai sitotoksik. Nilai IC_{50} bagi beberapa sebatian yang tidak dapat ditentukan dalam asai MTT terhadap sel kanser MCF-7 atau HCT 116 dianggap tidak aktif. Asai MTT terhadap MCF-7 menunjukkan hanya sebatian **6A** dan **7B** sahaja yang mempunyai aktiviti sederhana dengan nilai IC_{50} masing-masing iaitu 38 and 53 μ M. Lapan sebatian lain menunjukkan aktiviti anti-proliferasi yang sederhana lemah manakala enam sebatian lain menunjukkan aktiviti yang lemah. Asai MTT terhadap HCT 116 menunjukkan hanya sebatian **9A_{2-iii}** dan **9B_{2-iii}** yang melihatkan kesan sitotoksik

yang sederhana dengan nilai IC_{50} masing-masing yaitu 42 dan 56 μM . Tiga sebatian lain menunjukkan kesan perencatan yang kurang ke atas proliferasi sel dan lapan sebatian yang lain menunjukkan aktiviti yang lemah dengan nilai $IC_{50} > 110$. Keempat-empat terbitan baru 1,2,4-triazole yang berpotensi sebagai agen anti-proliferatif yang baik ialah sebatian **6A** ($IC_{50} = 38 \mu M$) dan **7B** ($IC_{50} = 53 \mu M$) terhadap sel kanser payudara manusia (MCF-7) sementara sebatian **9A2-iii** ($IC_{50} = 42 \mu M$) dan **9B2-iii** ($IC_{50} = 56 \mu M$) terhadap sel kanser kolon manusia (HCT 116).

SYNTHESIS, CHARACTERISATION AND CYTOTOXICITY STUDY OF SOME NEW 1,2,4-TRIAZOLE DERIVATIVES

ABSTRACT

In this study, 36 new 1,2,4-triazole compounds with mono and fused ring system have been synthesised and characterised. The mono system of 1,2,4-triazole derivatives have different moieties attached to the triazole ring. The first mono system showed four compounds of a pyridinium salt and a Schiff base moiety attached to the triazole ring, while the second mono system showed 24 compounds of a piperidinium salt and a Schiff base moiety attached to the triazole ring. The fused system of 1,2,4-triazole derivatives include three compounds with the triazole-oxadiazole fused ring and five compounds with the triazole-triazole fused ring. All these compounds were characterised using Fourier Transform Infrared (FT-IR) and Nuclear Magnetic Resonance (NMR) spectroscopy and carbon hydrogen nitrogen (CHN) elemental analysis. Some of the compounds were selected for cytotoxicity test in the search for potential anticancer agents, in particular for human breast tumor cells (MCF-7) and human colorectal tumour (HCT 116) cell. 35 compounds consisting of nine intermediates and 26 final compounds were tested for cytotoxicity assay. The IC_{50} for some of the compounds which could not be determined in the MTT assay against MCF-7 or HCT 116 cells were considered inactive. The MTT assay findings against MCF-7 showed that only compounds **6A** and **7B** indicated moderate activity of IC_{50} 38 and 53 μ M, respectively. Eight other compounds showed moderate to weak anti-proliferation activity while six other compounds showed weak activity. The MTT assay against HCT 116 showed that only compounds **9A_{2-iii}** and **9B_{2-iii}** demonstrated moderate cytotoxic effect with IC_{50} 42

and 56 μM , respectively. Three other compounds demonstrated lesser inhibitory effect on cell proliferation while eight other compounds showed poor activity with the IC_{50} of > 110 . These four new 1,2,4-triazole derivatives which showed potentials to become promising anti-proliferative agents are compounds **6A** ($\text{IC}_{50} = 38 \mu\text{M}$) and **7B** ($\text{IC}_{50} = 53 \mu\text{M}$) against human breast tumor cells (MCF-7) while **9A2-iii** ($\text{IC}_{50} = 42 \mu\text{M}$) and **9B2-iii** ($\text{IC}_{50} = 56 \mu\text{M}$) against human colorectal tumour cells (HCT 116).


CHAPTER 1

INTRODUCTION

1.1 Background of the research work


In the field of pharmaceutical organic chemistry, research is concentrated towards the introduction of new and safe therapeutic agents of clinical importance. Recently, the 5-membered ring heterocyclic compounds have proved their importance as being the centre of the biological activities (Kashyap et al., 2011). The nitrogen containing heterocycles are found in abundance in most of the medicinal compounds. Starting with imidazole as an important moiety of the medicinal agent, research work has led to the introduction of triazole which is an isostere of imidazole, in which the carbon atom of imidazole is isosterically being replaced by nitrogen (Bele and Singhvi, 2011).

Triazole is a 5-membered ring compound which contains two carbon and three nitrogen atoms. According to the position of the nitrogen atoms, the 5-membered triazole ring exists in two isomeric forms known as 1,2,3-triazole and 1,2,4-triazole, the former being known as *osotriazole*, and the latter as *triazole*. However, 1,2,4-triazole exists in two tautomeric forms of *1H* and *4H*-1,2,4-triazole (**1**), which is characterised by the position of the hydrogen (Finar, 1975, Singh and Chouhan, 2014, Shneine and Alaraji, 2016).




The discovery of 1,2,4-triazole ring represents an interesting class of compounds with promising biological activities (Valverde and Torroba, 2005) as antibacterial agent (Jayachandran et al., 2005; Matthew et al., 2007; Shaker, 2006; Swamy et al., 2010,), antimicrobial agent (Udupi et al., 2000a; Udupi et al., 2000b; Foroumadi et al., 2003; Hussain et al., 2008; Sharma et al., 2010; Upmanyu et al., 2011; Patil et al., 2013), anti-mycobacterial (Klimesová, et al., 2004), anticonvulsant (Plech et al., 2014), antifungal ((Mali et al., 2009, Luo and Hu, 2006), antidepressant (Düğdü et al., 2014, Chelamalla et al., 2012, Wakale et al., 2013) and anti-tuberculosis (Kaplancikli et al., 2005, Nandha et al., 2013).

Among these heterocycles, the mercapto- (**2**), thione- (**3**) and dithione- (**4**) substituted 1,2,4-triazole ring systems have been well studied and so far a variety of biological activities have been reported for a large number of their derivatives. This 1,2,4-triazole system with sulphur substituted compounds represents promising biological activities due to the presence of the NCS (=N-C-S) moiety in the compounds (Shaker, 2006).




The mercapto-1,2,4-triazoles, **2** are of great utility in the organic chemistry synthesis because in the presence of various reagents, these compounds undergo different types of reactions to yield interesting fused heterocyclic compounds such as triazolothiadiazolones (**5**), triazolothiadiazolothiones (**6**), triazolothiadiazines (**7**) and triazolothiadiazinones (**8**) (Holla et al., 2001; Abdel-Rahman et al., 2011; Siddiqui et

al., 2015). Compounds of triazoles fused to thiadiazines or thiadiazoles rings are also being incorporated into a wide variety of therapeutically important compounds, possessing a broad spectrum of biological activities (El Shehry et al., 2010, El-Sayed et al., 2010, Kamel and Abdo, 2014).



In the field of agrochemicals, the most common systems are generally 1,2,4-triazoles fused to pyridines (**9**), pyridazines (**10**), pyrimidines (**11**) and pyrazines (**12**). Pyridine heterocyclic moiety plays a vital role in the development of medicinal agents which are present in many products such as drugs, vitamins, food, plant dyes, adhesives and herbicides (Katrizky et al., 1996; Mohamed, 2010).



Several studies have also been reported on the fused 1,2,4-triazoles derivatives with other heterocyclic moieties such as triazole ring, **13** (Othman et al., 2014), oxadiazole ring, **14** (Somani and Shirodkar, 2009, Deshmukh et al., 2011) and thiazole ring, **15** (Erian et al., 2003, Andrew et al., 2008). Various thiazole derivatives are proven to be efficient for various diseases. They showed good physiological activities and are considered as good therapeutic agents such as anti

tubercular agents (E1-Shaer et al., 1998, Siddiquia et al., 2011) and antimicrobial agents (Guzeldemirci and Kucukbasmac, 2010, Liaras et al., 2011). Furthermore, diverse chemotherapeutic activities have also been ascribed to fused 1,2,4-triazolothiazole moieties as antimicrobial agents.



Schiff bases compounds have the imine or azomethine ($-C=N-$) functional group which is condensation products of the primary amines with carbonyl compounds. Schiff bases compounds have gained importance in medicinal and pharmaceutical fields due to their broad spectrum of biological activities. However, not many research work on the fused 1,2,4-triazole compounds with Schiff base moiety have been reported. This led to the formation of new ideas in the pharmacological and medicinal chemistry especially in the synthesis of therapeutically interesting molecules with better pharmacological functions for anticancer activity. Schiff bases of fused 1,2,4-triazoles have been found to possess extensive biological activities (Bekircan and Bektas, 2006; Bagihalli et al., 2008; Li et al., 2012, Farghaly et al., 2015; Gabr et al., 2015).

Cancer disease, a major worldwide problem is characterised by the proliferation and spreading of the abnormal cells. Therefore, the discovery and development of new potent and selective anticancer drugs are of high importance in modern cancer research. In spite of a large number of chemotherapeutic drugs

available for medical usage, the increasing resistance made it necessary to continue the search for new potential anticancer drugs.

1.2 Problem statement

New findings have established the fact that fused 1,2,4-triazole ring contributed great significance in the field of medicinal chemistry due to their versatile biological properties (Asif, 2014). However, these types of derivatives targeting specifically on the anticancer activity have not been widely explored (Holla et al., 2002; Holla et al., 2003; Demirbas and Uğurluoğlu, 2004a; Demirbas and Uğurluoğlu, 2004b; Sztanke et al., 2008; Bhat et al., 2009; Al-Issa, 2013, Hassan et al., 2013; Kamel and Abdo, 2014). Since a large number of fused 1,2,4-triazoles derivatives have shown pharmacological properties as anticancer agents, this research work focused on the modification of 1,2,4-triazole scaffold into various bioactive structures and their subsequent evaluation for cytotoxicity activities focusing on the colon and breast cancer cell lines (HCT and MCF 7) which are two of the common cancers.

1.3 Objectives

The main objectives of this project are:

1. To synthesise and characterise the mono system of 1,2,4-triazole derivatives which are divided into compounds with pyridinium salt and Schiff base moieties and compounds with piperidinium salt and Schiff base moieties.
2. To synthesise and characterise the fused system of 1,2,4-triazole derivatives which are divided into compounds with triazole-oxadiazole ring and compounds with triazole-triazole ring.
3. To evaluate the cytotoxic activity of all these compounds on the colon and breast cancer cell lines.

1.4 Scope of the Study



The research involved synthesizing some new 1,2,4-triazoles derivatives and characterisation work has been done using 1D and 2D NMR, FT-IR and CHNS elemental analysis. All these instruments are located at the School of Chemical Sciences. Samples for the anticancer work have been prepared and were sent to the Eman's Lab at Eureka.

CHAPTER 2

LITERATURE REVIEW

2.1 Compounds with 1,2,4-triazole core system

The discovery and development of new effective and selective anticancer drugs are of high importance in modern cancer researches (Ferlay et al., 2013). However, the fused 1,2,4-triazole compounds targeting specifically on the anticancer activity have not been widely explored. To date, only several studies on such compounds have been reported (Hou et al., 2011; Baviskar et al., 2012; Arul and Smith, 2014). Among the research work, the mercapto- and thione-substituted 1,2,4-triazole rings attached to a pyridine system have been of great interest due to the presence of the NCS (=N-C-S) moiety in the compounds (Shaker, 2006). 4-amino-5-(4-pyridyl)-4*H*-1,2,4-triazole-3-thiol derivatives showed very promising results on anticancer activity. The two isomers of 4-amino-5-(4-pyridyl)-4*H*-1,2,4-triazole-3-thiol molecule, known as thiol, **16** and thione, **17** exist in equilibrium (Creanga et al., 2010). The preparation of this 1,2,4-triazole derivatives produces two kinds of organic salts, **18** and **19**. (Ren and Jian, 2008).



Preparation of 4-amino-5-(4-pyridyl)-4*H*-1,2,4-triazole-3-thiol *via* cyclisation reaction of potassium 2-isonicotinoylhydrazinecarbodithioate gave a mixture of 1,2,4-triazole and its corresponding 1,3,4-oxadiazole derivatives, as shown in Figure 2.1. However, delicate work on the purification of this mixture afforded compound **18** in good purity but in low yield (Creanga et al., 2010).






Figure 2.1: Cyclisation of 1,2,4-triazole and 1,3,4-oxadiazole derivatives

Iqbal et al. (1996) reported the synthesis of new 1,2,4-triazoles compounds, 3-substituted thio-4-(2-phenylethyl)-5-(isomeric pyridyl)-1,2,4-triazoles, **21(a-c)** and **22(a-c)** derivatives from 4,5-disubstituted-1,2,4-triazoles **20(a-c)** using various isomers of pyridine carboxylic acid hydrazide with 2-phenylethyl isothiocyanate.




Iqbal et al. (1997) continued to synthesize a new series of 4-(4-halophenyl)-3-(isomeric pyridyl)-1*H*-1,2,4-triazoles-3-thion derivatives, **23(a-c)** through cyclisation reaction of 4-(isomeric pyridyl) thiosemicarbazide which was prepared from 4-halophenyl isothiocyanates with isomers of pyridyl carboxylic acid hydrazide.



23(a-c)

a: 2-pyridyl; **b:** 3-pyridyl; **c:** 4-pyridyl
X: F, Cl, Br

Banachiewicz et al. (2000) has reported two new systems of 4,4'-(1,4-phenylene)bis[5-(pyridin-4-yl)-4*H*-1,2,4-triazole-3-thiol] and 4,4'-(1,4-phenylene)bis[5-(pyridin-2-yl)-4*H*-1,2,4-triazole-3-thiol], **24(a-b)** via the condensation of *N'*-substituted amidrazones and *p*-phenylenediisothiocyanate.




24(a-b)

a: 2-pyridyl; **b:** 4-pyridyl


Zamani and his co-workers have conducted two independent studies in 2003 and 2004. The first study reported on the synthesis and characterisation of some new

compounds, **25(a-c)** without any biological or pharmacological activity work (Zamani and Faghihi, 2003). Later, other synthesis work on pyridyl and naphthyl substituted 1,2,4-triazole and 1,3,4-thiadiazole derivatives, **26(a-c)**, and their antimicrobial activity screening was reported (Zamani et al., 2004).



25(a-c)


a: 2-pyridyl; **b:** 3-pyridyl; **c:** 4-pyridyl
R: H(**a-c**); CH₃(**a-c**); C₂H₅(**a-c**);
 CH₂Ph(**a-c**); CH₂COOH(**a-c**)




26(a-c)

a: 2-pyridyl; **b:** 3-pyridyl; **c:** 4-pyridyl
R: H(**a-c**); CH₃(**a-c**); CH₂Ph(**a-c**)


Zhang et al. (2008) reported two new series of *S*-nucleosides of 5-(4-pyridyl)-4-aryl-4*H*-1,2,4-triazole-3-thiols *via* direct glycosylation of 5-(4-pyridyl)-4-aryl-4*H*-1,2,4-triazole-3-thiols **27(a-n)** which gave the corresponding derivatives, **28(a-n)**. The removal of the protecting groups using ammonia gas in dry methanol afforded the final series, **29(a-n)**. All these compounds have been tested against three different type of anti-HIV-1, the reverse transcriptase (RT), protease (PR) and integrase (IN) activities but none of these compounds showed good anti-HIV activity.



27(a-n)




28(a-n)



29(a-n)

R: Ph(**a**); *o*-C₂H₅OPh(**b**); *p*-C₂H₅OPh(**c**); *o*-CH₃OPh(**d**); *p*-CH₃OPh(**e**); *o*-CH₃Ph(**f**); *m*-CH₃Ph(**g**);
p-CH₃Ph(**h**); *o*-BrPh(**i**); *m*-BrPh(**j**); *p*-BrPh(**k**); *o*-ClPh(**l**); *m*-ClPh(**m**); *p*-ClPh(**n**);


Nadeem and Ashraf (2012) modified Zhang's work using some novel Mannich bases to prepare the *N*-nucleosides of 4-amino-5-substituted-1,2,4-triazole-3-thiones whereby their *in-vitro* antimicrobial activity was also examined. The original 1,2,4-triazoles molecules **30(a-j)** portrayed lower antibacterial activity compared to the corresponding protected nucleosides **31(a-j)** and the unprotected nucleosides **32(a-j)** against some selected bacteria.



2.2 Schiff base 1,2,4-triazole derivatives


Recently, some well-known 1,3,4-oxadiazole and 1,2,4-triazole systems were developed by Bayrak et al. (2009). Some new Schiff base, **33(a-b)** and Mannich base with an aliphatic cyclic amine such as morpholine or methyl piperazine, **35(a-c)** compounds were prepared. The corresponding Mannich base of compound **34** was reported to possess some biological activities.

refluxing acetic acid. All the derivatives obtained were used to synthesize of subsequent compounds of substituted triazolo[3,4-b][1,3,4]thiadiazines **39(a-p)**.



Ar = 4-pyridyl; 3-pyridyl
X = H, 4-Me, 4-OMe, 3-Br, 2-Cl, 4-Cl, 2-NO₂, 4-NO₂

Koparir et al. (2010) prepared some new arylidene-amino compounds with Schiff base unit, **40(a-d)**, via the reaction of 4-amino-5-(4-pyridyl)-4*H*-1,2,4-triazole-3-thione or 4-amino-5-(2-hydroxyphenyl)-4*H*-1,2,4-triazole-3-thione with a various aromatic aldehyde in anhydrous ethanol which was then converted into the corresponding Mannich base compounds, **41(a-d)**. It was reported that the thione-thiol forms are two tautomers, whereby the first tautomer exists in pure solid form.




X = a: H; b: 4-OMe; c: 4-OH, 3-OMe; d: 2,4-dihydroxy


Abdel-Rahman et al. (2011) synthesised a new compounds of arylidene-amino compounds with Schiff base unit, **42(a-b)** which then undergo cyclisation reaction to

form 3-(4-pyridyl)-6-aryl-7*H*-1,2,4-triazolo[4,3-*b*][1,3,4]thiadiazole, **43(a-b)**.


However, no biological activity studies were reported for these compounds.



Some new phenolic Schiff base compounds, **44(a-g)** have been synthesised from 4-amino-5-(4-hydroxyphenyl)-4*H*-1,2,4-triazole-3-thiol, followed by a condensation reaction with aromatic carbonyl compounds in refluxing methanol in the presence of traces of glacial ethanoic acid. Treatment of these compounds with thioglycolic acid gave compounds **45(a-g)** (Rajput, 2012).




Other significant Schiff base compounds were reported by Sachdeva et al. (2013) with good anti-inflammatory activities. 5-thiol-3-(4-pyridyl)-4*H*-1,2,4-triazol-4-yl-thiosemicarbazide, **46** was converted to 2-substituted-*N*-[3-(pyridin-4-yl)-5-sulfanyl-4*H*-1,2,4-triazol-4-yl]hydrazinecarbothioamide compounds, **47(a-j)** and **48(a-e)** via reaction of **46** with substituted aldehyde using the traditional technique and 1*H*-indole-2,3-di-ones using the microwave irradiation technique, respectively.




X = a: H; **b:** 4-NO₂; **c:** 2-Cl; **d:** 3-Cl; **e:** 4-Cl; **f:** 4-OCH₃;
g: 3,4,5-tri-OCH₃; **h:** 3-OH; **i:** 3-OH, 4-OCH₃; **j:** 4-F
R = a: H; **b:** 5-Cl; **c:** 5-Br; **d:** 5-CH₃; **e:** 5-NO₂

Some new compounds of **49(a-d)**, **50(a-d)** and **51(a-d)** can be obtained by refluxing the corresponding 4-amino-5-aryl-4*H*-1,2,4-triazole-3-thiol with 3-aryl-1*H*-pyrazole-4-carbaldehyde compounds in the presence of few drops of sulphuric acid as a catalyst in ethyl alcohol solvent. All these targeted compounds have been evaluated as potent antibacterial, antifungal and analgesic agents (Vijesh et al., 2013).




Ar = a: 2,4-dichlorophenyl; **b:** 4-thioanisyl; **c:** 2,5-dichlorothiophene **d:** biphenyl

Ding et al. (2010) reported an intermediate of potassium dithiocarbamate salt, **52** which undergone a ring closure with a surplus of 85% hydrazine hydrate to produce a corresponding phenolic 1,2,4-triazole, **53**, followed by the formation of Schiff base compounds, **54(a-h)**.




R = a: Ph; **b:** 4-F-Ph; **c:** 2-F-Ph; **d:** 4-Cl-Ph; **e:** 4-OCH₃-Ph;
f: 3-NO₂-Ph; **g:** Ph-CH=CH-; **h:** 2-Furyl

Other potassium dithiocarbamate salts, **55(a-f)** were reported by Gajera et al. (2012). Treatment of the salts with an excess of hydrazine monohydrate initiated the ring closure into the corresponding 1,2,4-triazole compounds, **56(a-f)**, followed by the condensation reaction to form the Schiff base compounds, **57(a-h)**.



R = a: H; **b:** 2-NH₂; **c:** 4-NH₂; **d:** 4-NO₂; **e:** 4-CH₃; **f:** 4-Cl
R₁/X = a: H/4-NO₂; **b:** 2-NH₂/4-NO₂; **c:** 4-NH₂/4-NO₂; **d:** 4-NO₂/2-OH;
e: 4-NO₂/4-NO₂; **f:** 4-CH₃/4-NO₂; **g:** 4-Cl/4-Cl; **h:** 4-Cl/4-OH


Wakale and Pattan (2015) reported a new Schiff base compounds of (*E*)-4-(substituted methylene amino)-5-(2-hydroxyphenyl)-4*H*-1,2,4-triazole-3-thiol, **58-59** via the synthesis pathway of 4-amino-1,2,4-triazole synthesis. Treatment of these compounds with thioglycolic acid in DMF produced two new series of 3-(3-(2-hydroxyphenyl)-5-mercapto-4*H*-1,2,4-triazol-4-yl)-2-substituted-thiazolidine-4-one, **60-61**, respectively. All these compounds were tested for antimicrobial activity. The biological study showed that the new molecules **59**, **60** and **61** exhibited the strongest inhibition against the microbial strains.



X = a: F; b: 4-OH; c: 4-OCH₃; d: 3-OCH₃, 4-OH; e: 2-Cl


2.3 1,2,4-Triazolo[4,3-b][1,2,4]thiadiazole derivatives

A variety of 1,2,4-triazolo[4,3-b][1,2,4]triazole compounds have been synthesised and their biological activity being reported. El-Ashry et al. (2006) synthesised 3-(3-chlorobenzo[b]-2-yl)-6-(*N,N*-dimethylamino)-1,2,4-triazolo[3,4-b][1,3,4]thiadiazole, **62** via microwave irradiation method. This technique was also used by Al-Abdullah et al. (2007) to synthesize 3-(1-adamantyl)-6-arylamino-1,2,4-triazolo[3,4-b][1,3,4]thiadiazole compound, **63** which showed good antimicrobial activities. Sodium 1-(6-phenylamino-1,2,4-triazolo[3,4b][1,3,4]thiadiazole-3-yl)heptadecane-1-sulfonate, **64** with good antibacterial activity was prepared by El-Sayed (2006).





Compounds with a similar scaffold of novel 1,2,4-triazolo[3,4-b][1,3,4]thiadiazole derivatives were reported by several groups. Salih (2008) reported the preparation and characterisation of 3-mercapto-6-amino-1,2,4-triazolo[3,4-b][1,3,4]thiadiazole, **65** while Shrivastava et al. (2010) reported 3-(2-(4-isobutylphenyl)propyl)-6-phenyl amine[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole, **66** with their good screening results as antimicrobial, analgesic and anthelmintic

activities. Al-Omar (2010) reported the synthesis of 3-(2-thienyl)-6-(4-sub-phenylamine)-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazole, **67** via microwave irradiation technique and their antimicrobial activity.




Other novel compounds encompassing of 1,2,4-triazole and 1,3,4-thiadiazole were also synthesised and characterised. Omprakash et al. (2011) reported a new compound of *N*-phenyl-3-(pyridin-3-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-phenyl amino, **68** having good antimicrobial activity. Abdel-Rahman et al. (2011) have reported new derivative of 3-(pyrid-4-yl)-6-phenylamino-1,2,4-triazolo[4,3-b][1,3,4]thiadiazole, **69**, showing anti-inflammatory and antimicrobial activities. Pandeya et al. (2012) synthesised two derivatives, **70** of 3(4-nitrophenyl)-*N*-phenyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole-6-phenyl amino and 3(phenyl)-*N*-phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole-6-phenyl amino with their antifungal and antibacterial activities. Harcharan et al. (2012) have reported a new compound of 3-(3-bromophenyl) [1,2,4]-triazolo[3,4-b][1,3,4]thiadiazol-6-amine, **71**, which was then converted to the corresponding new Schiff base compounds, **72**. All these compounds showed good antibacterial and antifungal activities.






2.4 1,2,4-Triazolo[4,3-b][1,2,4]triazole derivatives

A new system of fused 1,2,4-triazolo-triazole derivative such as 3-(pyridin-4-yl)6-amino-7*H*-1,2,4-triazolo[4,3-*b*][1,2,4]triazole was reported by Abdel-Rahman et al. (2011). The compound showed promising results for anti-inflammatory and antimicrobial activities.



2.5 1,2,4-Triazolo-3-thiolate derivatives

In this interesting study, Chemica et al. (2011) reported the interaction of 4-amino-5-(4-pyridyl)-4*H*-1,2,4-triazole-3-thiol, **74** with a cyclic secondary amines such as pyrrolidine and morpholine in anhydrous dimethyl sulfoxide formed the corresponding quaternary salts of pyrrolidinium 4-amino-5-(pyridin-4-yl)-4*H*-1,2,4-triazole-3-thiolate, **75** and morpholine-4-ium 4-amino-5-(pyridin-4-yl)-4*H*-1,2,4-triazole-3-thiolate, **76**, respectively. Similar reactions of *N*-(3-mercapto-5-(4-pyridyl)-4*H*-1,2,4-triazol-4-yl) isonicotinamide, **77** with morpholine and pyrrolidine yielded the quaternary salts of pyrrolidinium 4-isonicotinamido-5-(pyridin-4-yl)-4*H*-1,2,4-triazole-3-thiolate, **78** and morpholine-4-ium 4-isonicotinamido-5-(pyridin-4-yl)-4*H*-1,2,4-triazole-3-thiolate, **79**, respectively. These new salts were screened for their antibacterial and antifungal activity.



2.6 1,3,4-Oxadiazole-2-thiolate derivatives

Rutavicius et al. (2003) have also reported the interaction of 5-(4-pyridyl)-1,3,4-oxadiazole-2-thiol with piperidine or morpholine in dimethylformamide under reflux. The equivalent ratio of piperidine or morpholine in the solvent undergo cleavage of oxazole ring but in the presence of excess piperidine or morpholine in dimethyl sulfoxide, piperidinium 5-(pyridin-4-yl)-1,3,4-oxadiazole-2-thiolate, **80** and morpholin-4-ium 5-(pyridin-4-yl)-1,3,4-oxadiazole-2-thiolate, **81**, were formed, respectively.

